Bristol-Myers Squibb Stock Falls 2% After Patient Death in CAR-T Cell Therapy Trial
nashnova research
Bristol Myers Squibb disclosed that one multiple-sclerosis patient died in an early-stage trial of its CAR-T therapy zola-cel, sending shares down about 2% — the latest safety test for a program already on voluntary hold since September.
What happened to this patient?
The patient had highly active relapsing multiple sclerosis — a disease in which the immune system mistakenly attacks nerve tissue — and developed septic pneumonia after high-dose chemotherapy, dying the following day.
Death came 44 days after CAR-T cell infusion. The patient had also developed delayed motor symptoms that did not respond to two standard treatments.
This means → the death involved overlapping chemotherapy toxicity and infection, not a direct CAR-T cell kill — but the timeline still falls within the treatment-associated window.
Are other trial participants safe?
The trial enrolled 66 patients. 42.4% experienced cytokine release syndrome — a systemic inflammatory response triggered by immune-system overactivation — mostly brief and reversible.
Five patients developed immune-cell-related neurotoxicity, resolving in about two days. One progressive-MS patient had a severe event that resolved within four days after treatment.
In plain terms = side effects are not rare, but most have been manageable so far — the real warning signal is this single death.
Why was the study already on hold?
In September, Bristol Myers voluntarily paused all zola-cel studies, citing an "abundance of caution" safety-data review.
The immediate backdrop: rival Novartis had simultaneously paused eight trials of its own cell therapy, rap-cel.
This reflects a sector-wide safety reckoning for CAR-T in autoimmune disease — not a problem unique to Bristol Myers.
What does this mean for the market?
Shares fell roughly 2% in early trading — a relatively muted reaction, suggesting the market had partly priced in this risk.
Zola-cel targets CD19 protein — a marker on cells implicated in autoimmune disease. Across all autoimmune programs, 190 patients have received early-stage treatment with no other serious adverse events reported beyond this case.
This means → when — and whether — the therapy resumes clinical progress is the next key catalyst. The longer the hold lasts, the greater the uncertainty.
市场有风险，内容仅供研究参考，不构成投资建议。